Free tool
FAERS Monitor: Monistat 1 Combination Pack
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021308 or its brand name (Monistat 1 Combination Pack, Miconazole Nitrate). Reports on generic versions are filed under their own applications.
Reports
3,860
Serious
847
22% of reports
Hospitalization
337
Death reported
89
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- vulvovaginal burning sensation1,168
- drug ineffective737
- vulvovaginal pain685
- vulvovaginal pruritus388
- condition aggravated369
- vulvovaginal discomfort321
- vaginal haemorrhage290
- vulvovaginal swelling223
- pain111
- hypersensitivity100
- vaginal discharge94
- pruritus87
- abdominal pain86
- burning sensation85
- off label use83
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 20 |
| 2006 | 22 |
| 2007 | 13 |
| 2008 | 37 |
| 2009 | 66 |
| 2010 | 46 |
| 2011 | 46 |
| 2012 | 75 |
| 2013 | 18 |
| 2014 | 27 |
| 2015 | 35 |
| 2016 | 290 |
| 2017 | 292 |
| 2018 | 336 |
| 2019 | 325 |
| 2020 | 326 |
| 2021 | 373 |
| 2022 | 306 |
| 2023 | 223 |
| 2024 | 296 |
| 2025 | 350 |
| 2026 | 324 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,050,299 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| vulvovaginal burning sensationSignal | 1,168 | 1288.9 | 1219.4 | 1,215,053 |
| vulvovaginal painSignal | 685 | 903.0 | 838.2 | 528,843 |
| vulvovaginal swellingSignal | 223 | 757.7 | 661.0 | 147,313 |
| vulvovaginal pruritusSignal | 388 | 451.9 | 409.5 | 160,836 |
| vulvovaginal discomfortSignal | 321 | 426.7 | 382.5 | 126,055 |
| vaginal dischargeSignal | 94 | 51.1 | 41.8 | 4,524 |
| vaginal haemorrhageSignal | 290 | 36.6 | 32.8 | 9,972 |
| condition aggravatedSignal | 369 | 6.6 | 6.0 | 1,779 |
| burning sensationSignal | 85 | 6.6 | 5.4 | 400 |
| drug ineffectiveSignal | 737 | 3.0 | 2.9 | 1,079 |
| hypersensitivitySignal | 100 | 2.9 | 2.4 | 127 |
| abdominal painSignal | 86 | 2.0 | 1.6 | 43 |
| pruritus | 87 | 1.2 | 1.0 | 4 |
| pain | 111 | 1.0 | 0.8 | 0 |
| off label use | 83 | 0.5 | 0.4 | 39 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.